Hypothyroidism
Recent clinical, regulatory, research and industry developments relating to this disease.
Thyroid hormone and the Liver.
Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil.
Effects of thyroid hormones in skeletal muscle protein turnover.
Hypothyroidism and metabolic cardiovascular disease.
Investigating the shared genetic architecture between hypothyroidism and rheumatoid arthritis.
Subclinical Hypothyroidism in Patients with Obesity and Metabolic Syndrome: A Narrative Review.
Risks of suboptimal and excessive thyroid hormone replacement across ages.
Primary Hypothyroidism and Alzheimer's Disease: A Tale of Two.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
- Q4 2027Novel Approaches to the Treatment of Hypothyroidism
- Q1 2032Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism
Clinical MilestonesViewHide
- 2026-03-19Novel Approaches to the Treatment of HypothyroidismResults expected Q4 2027
- 2026-02-02Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical HypothyroidismResults expected Q1 2032
- 2026-01-05A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary HypothyroidismResults expected Q3 2027
- 2026-05-30ClinicalLetrozole Alone vs. Letrozole Plus Levothyroxine for Ovulation Induction in Infertile Women With Both (Polycystic Ovary Syndrome) PCOS and Sub-clinical Hypothyroidism.Primary completion
- 2026-03-19ClinicalNovel Approaches to the Treatment of HypothyroidismResults expected Q4 2027
- 2026-02-02ClinicalThyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical HypothyroidismResults expected Q1 2032
- 2026-01-05ClinicalA Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary HypothyroidismResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Lojuxta is indicated as an adjunct to a low?fat diet and other lipid?lowering medicinal p… (2013)
Approval — For the long-term treatment of growth failure in children and adolescents with severe pri… (2007)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Hypothyroidism8
- Thyroid Hormones3
- Thyroxine2
- Alzheimer Disease1
- Arthritis, Rheumatoid1
- Cardiovascular Diseases1
- Diabetes Mellitus, Type 21
- Homeostasis1
Leading journals6
- Frontiers in endocrinology2
- Cellular and molecular neurobiology1
- Endocrine reviews1
- European journal of endocrinology1
- Frontiers in immunology1
- Hepatology (Baltimore, Md.)1
Leading researchers8
- Biondi B2
- Bliddal S2
- Feldt-Rasmussen U2
- A Crimmins N1
- A Mencin A1
- A Xanthakos S1
- Al-Kuraishy HM1
- AlAnazi FH1
Affiliations (unnormalised)6
- Department of Clinical Medicine and Surgery3
- Academic Center for Thyroid Diseases1
- Almazov National Medical Research Centre1
- and Clinical Pharmacology1
- Azienda Ospedaliero-Universitaria Pisana1
- Bloomberg School of Public Health at Johns Hopkins University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Hypothyroidism is a syndrome caused by abnormally low secretion of thyroid hormones from the thyroid gland, which lowers basal metabolic rate. It can be primary, or secondary to pituitary disease or hypothalamic dysfunction. In severe cases, it can lead to mucopolysaccharide accumulation in the skin and edema, known as myxedema.
The grounding supports primary hypothyroidism and secondary hypothyroidism due to pituitary disease or hypothalamic dysfunction. It also indicates an autoimmune mechanism may contribute to thyroid dysfunction in related literature, but does not provide a specific causal statement for hypothyroidism itself beyond these categories.
Low thyroid hormone levels reduce metabolic activity and affect multiple target tissues, including liver, adipose tissue, pancreatic beta cells, skeletal muscle, and the cardiovascular system. The literature also links hypothyroidism with altered glucose and lipid metabolism, muscle protein turnover, and, in severe disease, mucopolysaccharide accumulation in the skin with edema.
Maternal hypothyroidism is reported as a risk factor for preterm birth. The literature also associates hypothyroidism with diabetes mellitus, obesity, metabolic syndrome, cardiovascular disease, and Alzheimer's disease, but the grounding does not establish these as causal risk factors for developing hypothyroidism.
The supplied literature supports thyroid hormone replacement as the main treatment category, specifically levothyroxine for subclinical hypothyroidism in some contexts. Thyrotropin, thyroxine, and triiodothyronine are the co-studied hormone-related agents, but the grounding does not support more specific treatment details.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.